Pharmaceutical

Gilead and LEO Pharma link on programmes for inflammatory conditions

Gilead and LEO Pharma have entered into a strategic collaboration to expedite the latter’s STAT6 programmes.

Jan 14, 2025 - 06:00
Gilead and LEO Pharma link on programmes for inflammatory conditions
Gilead and LEO Pharma have entered into a strategic collaboration to expedite the latter’s STAT6 programmes.
Read the original article

Tags:

Previous Article

Biogen proposes acquisition of partner Sage Therapeutics

Next Article

JP Morgan 2025: NVIDIA partners with IQVIA, Illumina and Mayo Clinic

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Evox Therapeutics teams with New York medical school to co-develop AAV vectors

Evox Therapeutics teams with New York medical school to...

Aug 4, 2023

The major biotech news updates you need to read today

The major biotech news updates you need to read today

Oct 4, 2023

Risk adjusted net present value: What is the current valuation of Merck’s MRNA-4157?

Risk adjusted net present value: What is the current va...

Nov 18, 2023